Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has entered into an agreement under which The Leukemia & Lymphoma Society (LLS) will support Curis’s ongoing ...
Related News:-
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical ...
{Businesswire via BioPortfolio} Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidate...
Curis Announces GDC-0449 Phase I Clinical Data Published In New ...
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, announced that two publications describing ...
In Play ® - Yahoo! Finance - The basics of investing.
Investing - Learn the basics of investing. Find tutorials, investing strategies and expert advice.
Ciprofloxacin : Reference (The Full Wiki)
Ciprofloxacin: MedlinePlus Drug Information 19 January 2010 8:49 ... Medical Information for consumers and providers
Fredericksburg.com - 122004
Fredericksburg, Virginia: The news and information source for the Fredericksburg, Virginia area.
BioTime Announces Agreement To Acquire Glycosan BioSystems
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it ...
RediClinic Announces Management Changes ( New Organizational ...
Health,... New Organizational Structure Positions Company for Growth in 2008...HOUSTON Nov. 7 /- In a series of management changesanno...Jack Koehn formerly chief operating ...
Optimum Online - Finance
Photos from Nintendo's Dedication of a Starlight Fun Center™ to Miller Children’s Hospital Long Beach with Jamie Lee Curtis Available on Business Wire's Website and AP ...
Financial Content - Financial Content Provider - Financial Data ...
Curis Announces FDA Acceptance and Priority Review of NDA for Vismodegib as Treatment for Advanced Basal Cell Carcinoma
No comments:
Post a Comment